Astellas’ Shinichiro Katayanagi On Taking A Measured Approach In Asia: An Interview With PharmAsia News (Part 1 of 2)
This article was originally published in PharmAsia News
Executive Summary
Astellas sets high internal requirements to enter a new market, sometimes giving itself only two to three years to turn profitable. Asia President Shinichiro Katayanagi leads with what works, often entering new markets on the back of Prograf and its core of key opinion leaders.
You may also be interested in...
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?